Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Evolocumab for treating hyperlipidaemia and mixed dyslipidaemia [ID765]

Provisional matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Amgen (evolocumab) Patient/carer groups • Afiya Trust • Black Health Agency • British Cardiac Patients Association • Cardiovascular Care Partnership • Coronary Prevention Group • Equalities National Council • Genetic Alliance UK • HEART UK • Muslim Council of Britain • Muslim Health Network • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance Professional groups • British Association for Nursing in Cardiac Care • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Inherited Metabolic Disease Group • British Society for Genetic Medicine • National Metabolic Biochemistry Network • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium Possible comparator manufacturers • Abbott Healthcare (fenofibrate) • Accord Healthcare (fluvastatin, pravastatin, simvastatin) • Actavis (atorvastatin, bezafibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) • Arrow Generics (atorvastatin, pravastatin, simvastatin) • Aspire Pharma (atorvastatin, fluvastatin) • AstraZeneca (rosuvastatin) • Aurobindo Pharma (simvastatin) • Bristol Laboratories (simvastatin) • Bristol-Myers Squibb (colestyramine, pravastatin) • Chanelle Medical UK (simvastatin) • Dexcel Pharma (atorvastatin, simvastatin)

Consultees	**Commentators (no right to submit or appeal)**
• Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Technology • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Genetic Testing Network • UK Health Forum <u>Others</u> • Department of Health • NHS Barking & Dagenham CCG • NHS England • NHS Walsall CCG • Welsh Government	• Discovery Pharmaceuticals (simvastatin) • Dr Reddy's Laboratories (atorvastatin) • Genus (fenofibrate) • Medreich (pravastatin, simvastatin) • Merck Sharp & Dohme (ezetimibe, simvastatin, simvastatin with ezetimibe) • Mylan (benzafibrate, fluvastatin, pravastatin, simvastatin) • Novartis Pharmaceuticals (fluvastatin) • Pfizer (acipimox, atorvastatin, colestipol, gemfibrozil) • Ranbaxy UK (atorvastatin, pravastatin, simvastatin) • Sandoz (bezafibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) • Sanofi (colesevelam) • Teva UK (atorvastatin, bezafibrate, colestyramine, fenofibrate, fluvastatin, gemfibrozil, pravastatin, simvastatin) • Wockhardt UK (atorvastatin, simvastatin) • Zentiva (atorvastatin, ciprofibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) <u>Relevant research groups</u> • British Society for Cardiovascular Research • Central Cardiac Audit Database • Cochrane Cystic Fibrosis and Genetic Disorders Group • Cochrane Heart Group • Health Research Authority • MRC Clinical Trials Unit • National Institute for Health Research • Society for the Study of Inborn Errors of Metabolism • Wellcome Trust - Cardiovascular Research Initiative <u>Evidence Review Group</u> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment

Consultees	**Commentators (no right to submit or appeal)**
	Programme <u>Associated Guideline Groups</u> • National Clinical Guidelines Centre <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.